iCo Therapeutics (OTCMKTS:ICOTF) Receiving Somewhat Favorable Media Coverage, Study Finds

Media coverage about iCo Therapeutics (OTCMKTS:ICOTF) has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. iCo Therapeutics earned a media sentiment score of 1.60 on their scale. InfoTrie also gave media headlines about the biotechnology company an news buzz score of 0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.

ICOTF traded up $0.03 on Tuesday, hitting $0.07. 9,800 shares of the company were exchanged, compared to its average volume of 11,023. iCo Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.13. The company has a fifty day moving average price of $0.04.

About iCo Therapeutics

iCo Therapeutics Inc, a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections.

Featured Article: Price to Earnings Ratio (PE)

Receive News & Ratings for iCo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.